Plus Therapeutics, Inc. (Nasdaq: PSTV) has received a delinquency notification from Nasdaq due to a delayed filing of its Quarterly Report on Form 10-Q for the period ended March 31, 2025. The company was informed on May 21, 2025, about its non-compliance with Nasdaq Listing Rule 5250(c)(1), which mandates timely filing of periodic financial reports with the SEC. Plus Therapeutics must submit a compliance plan by July 21, 2025, and is working to promptly file the report and normalize its filing schedule for the rest of the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.